Introduction
Triggering receptor expressed on myeloid cells 2 (TREM2) and TYRO protein tyrosine kinase binding protein (TYROBP) are part of the same receptor-signaling complex (Paloneva et al., 2002) .
Biallelic loss-of-function mutations in TYROBP or TREM2 genes cause polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL, Nasu-Hakola disease) (Paloneva et al., 2000 , Paloneva et al., 2002 , a rare disease characterized by pathologic fractures, personality changes and presenile dementia (Hakola, 1972) . In TYROBP, also known as DAP12, compound heterozygous mutations have been reported to cause PLOSL (Kuroda et al., 2007) whereas compound heterozygous mutations in TREM2 also lead to a frontotemporal dementia -like phenotype (Guerreiro et al., 2013) . TREM2 and TYROBP have also been genetically or functionally associated with Alzheimer's disease (AD), both late-onset (LOAD) (Jonsson et al., 2013 , Sims et al., 2017 , Zhang et al., 2013 and early-onset forms (Pottier et al., 2016 , Slattery et al., 2014 . While the association of TREM2 and AD seems strong, less data on TYROBP is available and it is inconclusive. However, a recent gene-regulatory network analysis of postmortem brains suggested TYROBP as an important regulator of gene expression in Alzheimer's disease (Zhang et al., 2013) .
In a cohort of 103 Turkish patients with different forms of dementia (average age of onset <66.7 years) a TYROBP p.Val55Leu variant was found in three individuals, but this variant was not considered pathogenic (Darwent et al., 2017) . In this article, we studied the effect of PLOSLFINdeletion of TYROBP on cognitive impairment.
In this study, we genotyped 3220 older Finns for the 5.3kb deletion in TYROBP that causes PLOSL in individuals of Finnish ancestry (Paloneva et al., 2000) and found no association with cognitive impairment.
Material and Methods

Cohorts
We studied four population-derived cohorts from the Finnish capital region (Helsinki area) from whom the 5.3kb TYROBP PLOSLFIN -deletion was genotyped and information on cognition was available. We also analyzed APOE alleles and APP p.Ala673Thr variant to compare the background genetic risk burden for cognitive impairment between TYROPB deletion carriers and non-carriers.
APOE ε4 is the most prevalent genetic risk factor for cognitive impairment and APP p.Ala673Thr is a strong protective mutation against Alzheimer's disease and age-associated cognitive decline (Jonsson et al., 2012 , Kero et al., 2013 .
The Helsinki Birth cohort study (HBCS) consists of 8760 individuals born in Helsinki in 1934 -1944 (Barker et al., 2005 , Eriksson et al., 2006 . In 2001-2004, a random sample of 2003 individuals participated in a clinical study including DNA extraction (Kajantie et al., 2012 , Yliharsila et al., 2007 and a random subsample's cognition was assessed with MMSE and CERAD. In addition, registry information up till December 31 of 2013 were checked for dementia hospitalizations and dementia deaths. This included data on diagnoses of any organic dementias, given by physicians in inpatient and outpatient (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) In [2002] [2003] 672 individuals who lived at home were randomly selected for analyses and 650 of them gave a venous blood sample. Participants' cognition was tested using the MMSE (Strandberg et al., 2016) . In 2014 cognition was evaluated with a questionnaire.
The DEBATE cohort consists of a random sample of 4,800 individuals living in Helsinki, Finland.
In 2000, 400 home-living individuals with stable cardiovascular disease (coronary artery disease, stroke or transient ischemic attack, peripheral artery disease) were clinically examined and cognitive functions were assessed with MMSE. (Uusvaara et al., 2013) In 2014 dementia diagnoses were screened from death certificates.
Vantaa 85+ Study includes 601 individuals, aged 85 years and older, who were living in the city of Vantaa, Finland. 553 individuals underwent neurological examination including MMSE by two neurologists in 1991-1992, with follow-up studies in 1994, 1996, 1999 and 2001. Neuropathological autopsy was performed on 281 individuals (Polvikoski et al., 1995) .
The study was approved by the Coordinating Ethics Committee of the Helsinki University Central
Hospital. The Vantaa 85+ study was also approved by the Ethics Committee of the Health Centre of the City of Vantaa.
Genotyping
Genomic DNA was available of 3260 samples from the four different cohorts. Samples from VV85+ were whole genome amplified DNA derived from peripheral blood leukocytes (PBLs).
DNA from other samples was derived from PBLs. We used PCR assay with one forward and two reverse primers to genotype the samples. Samples without the deletion produce one amplicon (~500bp), samples heterozygous for the deletion produce two amplicons(~500bp and ~700bp) and samples homozygous for the deletion produce only the larger amplicon (~700bp). Primer sequences were 5' GGCCACATCCGTATGACTG 3' for forward primer, 5' TAGTATGTCCAGTCTCGAGTTCTCA 3' for reverse primer 1 and 5' CTAGTCTGGGCGTGCATTC 3' for reverse primer 2. We used a positive control in all PCR assays.
We performed PCR in 20 µl reactions containing 100ng of DNA, 0.50 µl of Dynazyme II DNA polymerase (Thermo Scientific, Waltham, USA), 1.0 M Betaine (Affymetrix, Santa Clara, USA), 0.3 mM of dNTP (Thermo Scientific), 0.5 mM of each primer (Sigma-Aldrich, St.Louis, USA) and 1.0x optimized Dynazyme PCR buffer (Thermo scientific, Waltham, USA). PCR was started with an initial denaturation at 94˚for 12 min; followed by 40 cycles of 30 sec at 94˚, 15 sec at 60˚ (-1˚ for every cycle until at 55˚) and 30 sec at 72˚; and a final extension at 72˚ for 10 min. Amplicons were visualized in 2% agarose gel electrophoresis with ethidium bromide to determine the genotype of every sample.
APOE was genotyped as previously described (Myllykangas et al., 1999) . APP p.Ala673Thr was genotyped as previously described (Kero et al., 2013) .
Assessment of cognitive impairment
In the first analysis, we analyzed MMSE scores as a dichotomized variable where people with an MMSE score ≤24 were considered to have cognitive impairment. In the second analysis, MMSE scores were treated as a continuous variable. In a third analysis, we used cohort-specific information as complementary information. This information was, depending on cohort, a clinical diagnosis of dementia, any dementia diagnosis on death certificate, a questionnaire study with self-reported diagnoses and medications or hospital discharge and cause of death register information on any dementia diagnosis. In this third analysis, individuals with MMSE scores ≤24 or who had any diagnosis of dementia were considered to have cognitive impairment.
Statistical analyses
Analyses were conducted with SPSS v.24.0 (IBM Corp. Released 2016. IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp.). We used Fisher's exact test and Mann-Whitney U test to test for the association between cognitive impairment and the deletion. We used the same tests to study the differences in age, sex, APOE ε4 and APP p.Ala673Thr between deletion carriers and non-carriers.
Statistical power was calculated with the Genetic Power Calculator (http://zzz.bwh.harvard.edu/gpc/, accessed August 10, 2017) (Purcell et al., 2003) . Assuming deletion prevalence of 0.0034 based on our sequencing results, 20% prevalence of cognitive impairment in ≥75 years old Finnish population (Rahkonen et al., 2003) , relative risk of 2.5, casecontrol ratio of 4 and α=0.05, 423 cases were required for 80% power. This number of cases was achieved in all analyses.
Results
All cohorts together, we genotyped successfully 3220 (98.7%) individuals and 11 were heterozygous for the deletion, giving a total frequency of 0.0034. DEBATE was the only cohort with no deletion carriers (Supplementary Table1). No sample was homozygous for the deletion as could be expected. A summary of the characteristics of the 11 deletion carriers is shown in Supplementary Table2. MMSE scores were available for 2390 individuals, including seven deletion carriers. In the first analysis, 497 non-carriers (21%) and one deletion carrier (14%) had cognitive impairment (MMSE ≤24) (Fisher's exact test p=1). When MMSE scores were analyzed as a continuous variable, there was no significant difference between deletion carriers and non-carriers (Mann-Whitney U test p=0.68). In the third analysis, any information on cognition (MMSE, questionnaire, diagnosis of dementia) was retrieved from 3192 individuals including all 11 deletion carriers. Of the deletion carriers, three (27%) and of the non-carriers 692 (22%) had cognitive impairment (Fisher's exact test p=0.71). In all three analyses there were no statistically significant differences between carriers and non-carriers in age, sex, APP p.Ala673Thr or APOE ε4 status. In the first and second analyses, deletion carriers vs. non-carriers had the following characteristics: mean age 77,9 vs. 76,1 years (mean ranks 1350 vs 1195, p=0.55), 57.1 % vs. 44,9% females (p=0.71) and 28.6 % vs. 32,4 % had the APOE ε4 allele (p=1.0). In the third analysis deletion carriers vs. non-carriers had the following characteristics: mean age 77.6 vs. 78,9 years (mean ranks 1463 vs 1596 p=0.63), 54.5 % vs. 46,7 % females (p=0.76) and 45.5% vs. 32.9 % (p=0.52) . There were 23 (0.7%) carriers of the APP p.Ala673Thr variant, none among the TYROBP deletion carriers (p=1.0 in all analyses).
Two subjects of the Vantaa85+ study were autopsied at the ages of 89 and 94.Their mean percentage of the cortex covered by methenamine silver-positive senile plaques in sections cut from 4 neocortical samples (neocortical beta-amyloid percentages) were 0% and m 0.18%, both had a CERAD score of 0 and Braak stages 3 and 4. These neuropathological features do not show significant signs of AD pathology. The mean beta-amyloid percentages in the Vantaa85+ population were 3.4%, Braak stage 3.3 and CERAD 1.4 (in the Vantaa 85+ study: score 1= sparse neuritic senile plaques, 2 = moderate frequency of neuritic senile plaques, 3= frequent neuritic senile plaques).
We performed logistic regression analyses to study the effect of APOE ε2 and ε4 carriership on cognitive impairment and used age and sex as covariates. APOE ε4 carriership associated with cognitive impairment in both MMSE score -based analysis (p=2.3 x 10 -4 , OR 1.7 (1.3-2.3)) and when all information available on cognition was used (p=2.4 x 10 -9 , OR=1.9 (1.5-2.4)). APOE ε2 associated with better cognition when using cognitive impairment status derived from MMSE scores (p=0.019, OR=0.6 (0.39-0.92)) and showed a trend for better cognition when all information available on cognition was used (p=0.07, OR=0.74 (0.54-1.03)).
Discussion
We used MMSE scores and dementia diagnoses to study cognitive impairment on PLOSLFIN deletion carriers and non-carriers and found no statistically significant differences.
Neuropathological data on two deletion carriers brings additional support that the deletion is not a major risk factor for Alzheimer's disease. On the contrary, both had very low neocortical betaamyloid percentages and CERAD scores, which is noteworthy because it is known that TREM2 and TYROBP expressing microglia accumulate around senile plaques but whether the effect is beneficiary or harmful is still under debate.
To the best of our knowledge, we report the first data on cognition and neuropathological examination of older individuals with a heterozygous PLOSL-causing TYROBP variant. Our results suggest that the deletion is not a major risk factor for cognitive impairment. The main limitations of our study arise from the rarity of the PLOSLFIN -deletion and larger studies are needed to exclude minor effects on cognition. Moreover, it is not known how much TYROBP protein levels decrease in the deletion carriers since we were not able to study the expression level of TYROBP.
High socioeconomic status is also known to be a protective factor against cognitive impairment and MMSE test may lose some of its sensitivity with highly-educated people. Unfortunately, we did not know the socioeconomic status of most of the participants and could not include the effect of socioeconomic status into our analyses.
The VV85+ samples were whole-genome amplified DNA whereas other samples were genomic DNA extracted from blood. Amplification is a potential source of error when studying larger deletions. In our study, however, the frequency of the studied deletion in the VV85+ samples was in line with the other cohorts suggesting no error occurred during whole genome amplification. 
